Everfront Biotech Holding, which is developing implantable wafers and oral therapies for hard-to-treat diseases, filed on Friday with the SEC to raise up to $10 million in an initial public offering.
Everfront Biotech is developing effective strategies for combating hard-to-treat diseases such as glioblastoma (GBM), pancreatic cancer (PC), and amyotrophic lateral sclerosis (ALS). The company's most advanced candidate, its implantable Cerebraca Wafer, is being developed for in-situ drug delivery after surgical resection, and has completed a Phase 1/2 trial in recurrent GBM patients. Everfront is also developing another implantable wafer for PC, as well as soft-gel capsules as oral maintenance therapies for ALS, GBM, and PC.
The Taipei City, Taiwan-based company was founded in 2010 and plans to list on the Nasdaq under the symbol EFB. Everfront Biotech Holding filed confidentially on June 14, 2024. Roth Capital and The Benchmark Company are the joint bookrunners on the deal. No pricing terms were disclosed.
